Alongside trials exploring BRAF inhibitors alone, BRAF and MEK inhibitors are being explored as combination therapy to reduce the possibility of tumor resistance commonly associated with single-agent BRAF inhibitors. The gene discussed is MAP2K7; the disease is neoplasm.